PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome

Multiple clinical studies have correlated gene expression with survival outcome in cancer on a genome-wide scale. However, in many cases, no obvious correlation between expression of well-known tumour-related genes (that is, p53, p73 and p21) and survival rates of patients has been observed. This can be mainly explained by the complex molecular mechanisms involved in cancer, which mask the clinical relevance of a gene with multiple functions if only gene expression status is considered. As we demonstrate here, in many such cases, the expression of the gene interaction partners (gene ‘interactome’) correlates significantly with cancer survival and is indicative of the role of that gene in cancer. On the basis of this principle, we have implemented a free online datamining tool (http://www.bioprofiling.de/PPISURV). PPISURV automatically correlates expression of an input gene interactome with survival rates on >40 publicly available clinical expression data sets covering various tumours involving about 8000 patients in total. To derive the query gene interactome, PPISURV employs several public databases including protein–protein interactions, regulatory and signalling pathways and protein post-translational modifications.

[1]  D. Green,et al.  The Cul4A–DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity , 2013, Oncogene.

[2]  Rafael C. Jimenez,et al.  The IntAct molecular interaction database in 2012 , 2011, Nucleic Acids Res..

[3]  Yong Liao,et al.  Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients , 2004, Clinical Cancer Research.

[4]  Richard D Riley,et al.  A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[5]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[6]  Gerry Melino,et al.  p73 in Cancer. , 2011, Genes & cancer.

[7]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[8]  Dennis B. Troup,et al.  NCBI GEO: archive for high-throughput functional genomic data , 2008, Nucleic Acids Res..

[9]  G. Tortora,et al.  Inhibition of bcl-2 as cancer therapy. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Henning Hermjakob,et al.  R spider: a network-based analysis of gene lists by combining signaling and metabolic pathways from Reactome and KEGG databases , 2010, Nucleic Acids Res..

[11]  Z. Szallasi,et al.  Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. , 2012, Endocrine-related cancer.

[12]  Bin Zhang,et al.  PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..

[13]  A. Gartel,et al.  Lost in transcription: p21 repression, mechanisms, and consequences. , 2005, Cancer research.

[14]  Carlos Caldas,et al.  Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index , 2006, Clinical Cancer Research.

[15]  Gene Ontology Consortium.  The Gene Ontology (GO) database and informatics resource , 2003 .

[16]  R. Knight,et al.  MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets , 2012, Cell Death and Differentiation.

[17]  Alexey V. Antonov,et al.  BioProfiling.de: analytical web portal for high-throughput cell biology , 2011, Nucleic Acids Res..

[18]  A. Levine,et al.  The p53 family: guardians of maternal reproduction , 2011, Nature Reviews Molecular Cell Biology.

[19]  D. Harrington.  A class of rank test procedures for censored survival data , 1982 .

[20]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F M Blows,et al.  BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received , 2010, British Journal of Cancer.

[22]  Alexey V. Antonov,et al.  CCancer: a bird’s eye view on gene lists reported in cancer-related studies , 2010, Nucleic Acids Res..

[23]  W. Gu,et al.  The multiple levels of regulation by p53 ubiquitination , 2010, Cell Death and Differentiation.

[24]  E. Flores,et al.  Pirh2, a Ubiquitin E3 Ligase, Inhibits p73 Transcriptional Activity by Promoting Its Ubiquitination , 2011, Molecular Cancer Research.

[25]  Kimberly Van Auken,et al.  WormBase: a multi-species resource for nematode biology and genomics , 2004, Nucleic Acids Res..

[26]  A. Venturino,et al.  Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. , 1999, Anticancer research.

[27]  T. Mak,et al.  The impact of p53 and p73 on aneuploidy and cancer. , 2008, Trends in cell biology.

[28]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[29]  M. Miura,et al.  Resistance to Fas-mediated apoptosis: activation of Caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP , 1998, Oncogene.